Smartleaf Asset Management
LENZ icon

Smartleaf Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Smartleaf Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-37
Closed -$213 – 3834
2026
Q2 		$213 Hold
37
– – ﹤0.01% 3299
2026
Q1 		$307 Sell
37
-152
-80% -$2.14K ﹤0.01% 3290
2025
Q4 		$3.05K Buy
189
+178
+1,618% +$5.19K ﹤0.01% 2859
2025
Q3 		$493 Buy
+11
New +$404 ﹤0.01% 2858
2025
Q2 		– Sell
-11
Closed -$282 – 2995
2025
Q1 		$282 Hold
11
– – ﹤0.01% 2765
2024
Q4 		$330 Hold
11
– – ﹤0.01% 2832
2024
Q3 		$264 Hold
11
– – ﹤0.01% 2851
2024
Q2 		$195 Buy
+11
New +$192 ﹤0.01% 2681

Other funds holding LENZ

Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Smartleaf Asset Management's LENZ Position: Q3 2026 in Review

Smartleaf Asset Management sold out of LENZ Therapeutics (LENZ) in Q3 2026, closing a stake of 37 shares — an estimated $213 sold.

Smartleaf Asset Management first reported a position in LENZ in Q2 2024 and held it in 8 quarters. The position peaked at $3.05K in Q4 2025. 55 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

  • Smartleaf Asset Management reported no remaining LENZ Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Smartleaf Asset Management sold 37 LENZ Therapeutics shares in Q3 2026, an estimated $213.
  • Smartleaf Asset Management first reported a position in LENZ Therapeutics in Q2 2024 and held it in 8 quarters.
  • Smartleaf Asset Management's LENZ Therapeutics position peaked at $3.05K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.